Phase II Study of Rituximab Combined With ESHAP in Patients With Relapse or Refractory DLBCL
The salvage therapy in the patients with DLBCL is still controversial. The investigators
conducted this study to evaluate the efficacy and tolerability of Rituximab combined with
ESHAP in the patients with DLBCL. The patients enrolled were defined to be relapsed or
refractory after the first-line chemotherapy like CHOP or other CHOP-like regimens.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Biyun Wang, M.D.
China: Ethics Committee